US Patent 10,434,059: Scope, Claims, and U.S. Patent Landscape
US Drug Patent 10,434,059 claims a topical pharmaceutical composition built around isopropyl myristate combined with a defined catechol mixture dominated by (−)-epigallocatechol gallate (EGCG gallate) and containing lower fractions of (−)-epicatechol, (−)-epicatechol gallate, (−)-epigallocatechol, (−)-gallocatechol, and (−)-gallocatechol gallate. The patent also claims methods for treating papilloma virus-induced skin disease or benign tumor disease caused by a broad HPV genotype panel, using the claimed composition.
What is the core protected subject matter?
Product-by-composition claim structure (independent claim 1)
Claim 1 protects a pharmaceutical composition with two coupled quantitative elements:
1) Catechol mixture (w/w percent ranges)
- 4-15% (−)-epicatechol
- 2-20% (−)-epicatechol gallate
- 3-15% (−)-epigallocatechol
- 40-75% (−)-epigallocatechol gallate
- 0.1-1% (−)-gallocatechol
- 1-10% (−)-gallocatechol gallate
2) Isopropyl myristate loading
- The pharmaceutical comprises at least 5-50% (w/w) isopropyl myristate.
Claim 1 also requires that the pharmaceutical composition includes at least 5-50% (w/w) isopropyl myristate, tying the delivery/lipid phase to the specific catechol profile.
Claim 2-6 narrow the composition by fixing the relative w/w amounts of catechol mixture and isopropyl myristate, including:
- Claim 2: 1-30% catechol mixture and at least 10-50% isopropyl myristate
- Claim 3: 2-20% catechol mixture
- Claim 4: 15-18% catechol mixture
- Claim 5: at least 25-50% isopropyl myristate
- Claim 6: at least 35-50% isopropyl myristate
Product formula lock-in (composition-dependent claims)
Claims 10 and 19 and 26 act as “anchor” embodiments.
-
Claim 10 provides a specific catechol distribution:
- 10.8% (−)-epicatechol
- 6.5% (−)-epicatechol gallate
- 9.2% (−)-epigallocatechol
- 54.8% (−)-epigallocatechol gallate
- 4.0% (w/w) (−)-gallocatechol gallate
(and by context the remaining portion aligns to the defined catechol set)
-
Claim 19 provides a full exemplar topical formulation (35% isopropyl myristate; 15% catechol mixture; plus petroleum jelly, wax, stearyl ester-type excipient, oleyl alcohol).
-
Claim 26 provides an alternative exemplar where petroleum jelly/wax/ester/excipient system changes to white petrolatum + white wax while keeping the isopropyl myristate and catechol-mixture fractions the same.
Treatment-by-use claim structure
The method claim is framed around:
- Patient treatment for papilloma virus-induced skin disease or benign tumor disease
- Administering a pharmaceutical composition of claim 19
- A large enumerated list of HPV genotypes (claim 21)
- Expanded disease mapping into specific wart and tumor categories (claims 22-23)
- Topical application (claim 24) and genitally/vaginally (claim 25)
How broad is the catechol-mixture protection?
Quantitative “range” coverage in claim 1
The catechol mixture is not protected as a generic “green tea extract rich in catechins.” It is protected as a specific compositional profile with these key constraints:
-
EGCG gallate dominance: 40-75%
This is the single most restrictive feature. Most non-fractionated catechin extracts will vary; many will not guarantee this dominance as a stable, composition-defined percentage band.
-
(−)-gallocatechol gallate present but controlled: 1-10%
-
(−)-gallocatechol present at trace-low level: 0.1-1%
This two-parameter constraint (gallocatechol gallate and gallocatechol) narrows freedom in formulation or extract sourcing.
-
Other catechols are each in capped bands:
- epicatechol 4-15%
- epicatechol gallate 2-20%
- epigallocatechol 3-15%
Specific embodiment narrowing
-
Claim 10 locks in a particular catechol profile with EGCG gallate at 54.8%, consistent with the dominance band.
-
Claim 14 adds a sourcing limit: catechols are isolated from a tea extract.
Scope implication: protection spans any catechol mixture that fits the six-component w/w distribution bands. It also extends to the same compositional profile even when the catechols are generated by separation from a tea extract, so long as the resulting catechol profile matches the bands in claim 1.
How broad is the formulation / delivery protection?
Isopropyl myristate loading bands
Claim 1 covers isopropyl myristate at 5-50% (w/w) (minimum and maximum implied by the claim language).
Dependent claims push the composition toward higher lipid loading:
- Claim 2: isopropyl myristate at least 10-50%
- Claim 5: at least 25-50%
- Claim 6: at least 35-50%
Exemplars with full excipient stacks
Claim 19 (and claim 26) matter for enforcement because they are complete, closed-form examples:
Claim 19 exemplar (topical composition)
- 35% isopropyl myristate
- 15% catechol mixture with bands:
- epicatechol 4-15%
- epicatechol gallate 2-20%
- epigallocatechol 3-15%
- EGCG gallate 40-75%
- gallocatechol 0.1-1%
- gallocatechol gallate 1-10%
- excipients:
- 24.5% petroleum jelly
- 20% wax
- 5% propylene glycol monostearate or propylene glycol monopalmitostearate
- 0.5% oleyl alcohol
Claim 26 exemplar
- 35% isopropyl myristate
- 15% catechol mixture (same band description)
- excipients:
- 35% white petrolatum
- 25% white wax
- 5% propylene glycol monopalmitostearate
- 0.5% oleyl alcohol
Additives and auxiliary substances
Claim 17 and 18 broaden excipient latitude but narrow the type:
- Claim 17: may include additives/auxiliary substances
- Claim 18: hydrophobic additives selected from:
- petroleum jelly
- wax
- oleyl alcohol
- propylene glycol monostearate
- propylene glycol monopalmitostearate
Scope implication: a generic “catechol + isopropyl myristate” product likely infringes claim 1 when catechol profile matches. The excipient stack is then a secondary axis: claim 17/18 allow hydrophobic excipients from a defined group, but claim 19/26 lock in exact exemplars that support the method claim.
How broad is the method/use protection?
HPV genotype coverage
Claim 21 enumerates HPV types:
1, 2, 3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19-29, 31, 32, 34, 36-38, 46-50, 56, or 58.
That is a very wide coverage set, with key clinically common types included (e.g., 16, 18, 6, 11, 31, 33-range via 19-29, 45 not listed but nearby ranges are).
Disease categories
Claim 22 covers:
- warts or genital warts
- benign tumors of skin and/or mucosa
Claim 23 enumerates specific benign tumor/wart forms, including:
- verrucae plantares
- verrucae vulgares
- verrucae planae juveniles
- epidermodysplasia verruciformis
- Condylomata acuminata
- Condylomata plana
- bowenoid papulosis
- papillomas on the larynx and oral mucosa
- focal epithelial hyperplasia
Route of administration
- Claim 24: topical application
- Claim 25: genitally or vaginally
Scope implication: the method claims are not limited to a single anatomical location. They require topical administration, with dependent claims expanding to genital/vaginal route.
What claim elements are most likely to drive infringement?
Most important infringement “tripwires”
1) Catechol profile bands (6-component distribution constraints)
2) Isopropyl myristate loading meeting claim 1 minimum and dependent thresholds
3) For the method claims, at least the composition of claim 19 must be administered
Claim hierarchy effects
- If a competitor’s product contains isopropyl myristate and a catechol mixture with the six-component distribution within the bands of claim 1, product infringement risk rises for the composition claims.
- For method infringement, the competitor must administer a formulation matching claim 19 (or fall within its scope through equivalence or claim construction), then treat one of the claimed HPV-induced conditions.
How does the patent landscape likely look around this chemistry and indication?
Landscape axis 1: catechin fractions and EGCG-dominant mixtures
US 10,434,059 ties the active profile to a specific catechin distribution rather than “total catechins.” This suggests competitive space where:
- Extracts (tea-derived or otherwise) are fractionated to hit EGCG gallate dominance and control gallocatechol and gallocatechol gallate.
- Competitors may try to steer out of the bands by shifting component ratios, especially around:
- 40-75% EGCG gallate
- 0.1-1% gallocatechol
- 1-10% gallocatechol gallate
Landscape axis 2: fatty ester topical delivery vehicles
The repeated role of isopropyl myristate plus hydrophobic bases (petrolatum/wax/oleyl alcohol and propylene glycol stearate-type esters) indicates that delivery formulation protection can be a key barrier. Competitors may attempt:
- Different lipid esters
- Different polar co-solvents
- Different wax/petrolatum systems
Landscape axis 3: HPV wart topical regimens
Claim scope is tied to a broad HPV genotype and disease mapping. In the broader landscape, topical wart treatment space typically includes:
- immunomodulators
- keratolytics
- antiviral approaches
- topical chemotherapy approaches
US 10,434,059 positions a catechin-lipid topical composition as the therapeutic agent for HPV-induced warts/benign tumors.
A practical freedom-to-operate lens for US 10,434,059
If you are developing a similar topical product
Your “design-out” choices revolve around staying outside at least one critical limitation:
- Catechol component percentages outside the claimed bands (especially EGCG gallate, gallocatechol, and gallocatechol gallate)
- Isopropyl myristate loading below the claim minimum or substituting it with a different ester (for compositions targeting claim 1)
- For methods: avoiding treatment use claims mapped to HPV-genotype list and disease categories, while also using a formulation not falling into claim 19’s specific excipient stack
If you are developing a similar indication with different composition
Even if the indication overlaps (HPV warts/benign tumors), method claims depend on administering the claimed composition. A competitor with a different catechin fraction profile or different vehicle likely reduces method-claim exposure.
Key Takeaways
- US 10,434,059 is anchored on a topical pharmaceutical composition combining isopropyl myristate with a defined six-component catechol mixture, with EGCG gallate at 40-75% as the central compositional constraint.
- The composition claims are quantified by w/w bands for each catechol and by isopropyl myristate loading (5-50% and higher in dependent claims).
- The method claims cover HPV-induced skin disease/benign tumors with a broad HPV genotype panel and explicitly require topical administration, with dependent coverage extending to genital/vaginal application.
- The enforcement pathway for methods runs through claim 19’s exemplar formulation (35% isopropyl myristate, 15% catechol mixture with the band definitions, plus petroleum jelly/wax/propylene glycol stearate-type excipient and oleyl alcohol).
- The most actionable infringement risks for a competitor are catechol-ratio compliance and isopropyl myristate inclusion, followed by claim 19 formulation matching for treatment use.
FAQs
1) Does US 10,434,059 protect “catechins” broadly or a defined catechol distribution?
It protects a defined distribution of six catechols by w/w percentage, with EGCG gallate at 40-75% and controlled levels of gallocatechol and gallocatechol gallate.
2) Is isopropyl myristate required in all claims?
Yes. Claim 1 requires at least 5-50% (w/w) isopropyl myristate, with dependent claims requiring higher minimums.
3) Are the method claims limited to a single HPV type or a broad list?
They cover a broad enumerated list of HPV genotypes in claim 21.
4) Does topical application matter?
Yes. Claim 24 requires topical application, and claim 25 specifies genitally or vaginally.
5) What is the practical difference between the composition claims and the method claims?
Composition claims hinge on meeting the quantitative composition bands. Method claims hinge on administering the specific composition of claim 19 for the listed HPV-related diseases.
References
[1] United States Patent and Trademark Office. US Patent 10,434,059 (claims provided).
